Many suffer from Moderate or Mild Sleep Apnea which make up over 80% of the population suffering from Sleep Apnea
Currently, the number of patients with depression is increasing rapidly
Reflecting these advantages, the 2023 treatment algorithm for type 2 diabetes, published by the Japanese Diabetes Society, recommends GLP-1 RAs for patients with cardiovascular disease or chronic kidney disease, anticipating additional benefits [35, 36]
Both offer promising paths to a leaner, healthier body
On the other hand, the upregulation of MMP-9 and MMP-2 in the peripheral nerves contributes to the development and maintenance of neuropathic pain after CCI
It is particularly helpful for those who experience constant hunger, difficulty controlling portions, or metabolic resistance to weight loss